The Technical Signals Behind (AGIO) That Institutions Follow
This article analyzes Agios Pharmaceuticals Inc. (NASDAQ: AGIO), highlighting strong near and mid-term sentiment but a weak long-term outlook. It identifies no resistance levels above the current price, suggesting upside potential. The piece provides AI-generated trading strategies (position, momentum breakout, risk hedging) and a multi-timeframe signal analysis for AGIO.
Agios Pharmaceuticals (AGIO) Could Be 8% Below Fair Value On Growth Index Shift
Agios Pharmaceuticals (AGIO) has been reclassified into several Russell growth benchmarks, shifting away from value-defensive indices, following a strong recent performance in its share price. Despite this, the company is considered modestly undervalued by some narratives, with a fair value of $40.88 against a last close of $37.58, driven by potential FDA approval for PYRUKYND. However, its high price-to-sales ratio raises valuation concerns, while mixed signals suggest both risk and reward for investors.
Price to book forward of Agios Pharmaceuticals, Inc. – NASDAQ:AGIO
The article provides financial data on Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), specifically its price to book forward metric. It also lists various financial tools and resources available on TradingView, covering markets, community features, and business solutions.
AGIO - Agios Pharmaceuticals Inc Latest SEC Filings
This page provides the latest SEC filings for Agios Pharmaceuticals Inc (AGIO), including financial data, trading performance metrics, and key company statistics. It details market capitalization, income, sales, various ratios, analyst recommendations, and recent stock performance indicators. The content is presented as a snapshot of the company's financial health and market position.
Price to earnings forward of Agios Pharmaceuticals, Inc. – NASDAQ:AGIO
This page provides financial information for Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), specifically its price-to-earnings forward ratio. It highlights that the market is closed, with no trades, and offers various data points and resources related to the company's financials on the TradingView platform.
Agios Pharmaceuticals: CMO Sarah Gheuens sells $150,502 in stock By Investing.com
Sarah Gheuens, CMO of Agios Pharmaceuticals, sold 4,007 shares of company stock worth $150,502 to cover tax obligations related to restricted stock unit vesting. This transaction followed a 10b5-1 trading plan established in 2023. Gheuens simultaneously acquired 8,375 shares through vesting and now directly holds 84,645 shares, while the stock shows strong momentum and appears undervalued according to InvestingPro.
Agios (NASDAQ: AGIO) CMO nets shares after RSU vesting and tax sale
Agios Pharmaceuticals' Chief Medical Officer, Sarah Gheuens, reported a routine equity transaction where 8,375 restricted stock units vested and converted into common shares. To cover tax obligations, 4,007 shares were sold at $37.56 each under a pre-arranged 10b5-1 plan. Following these transactions, Gheuens directly holds 84,645 shares of Agios common stock.
D. E. Shaw reports 3.03M-share stake in Agios (AGIO)
D. E. Shaw & Co., L.P. and David E. Shaw have reported a 5.1% stake in Agios Pharmaceuticals (AGIO), totaling 3,034,031 shares, through a Schedule 13G SEC filing. The filing indicates shared voting power over 2,863,931 shares and shared dispositive power over all 3,034,031 shares. While David E. Shaw disclaims direct beneficial ownership, the shares are held across several managed vehicles.
AGIO (NASDAQ: AGIO) affiliate notifies plan to offer 4,007 shares via broker
An affiliate of Agios Pharmaceuticals (NASDAQ: AGIO) has filed a Form 144, indicating a plan to offer 4,007 shares of common stock. These shares are associated with the vesting of restricted stock units on July 1, 2026, and will be sold through Morgan Stanley Smith Barney LLC. The filing also notes a previous sale of 2,940 shares by Sarah Gheuens on April 2, 2026, for $102,047.40.
How Agios Pharmaceuticals' Shift Into Russell Growth Indices Will Impact Agios Pharmaceuticals (AGIO) Investors
Agios Pharmaceuticals (AGIO) has been added to several Russell growth benchmarks, including the Russell 2000 Growth, indicating an increasing perception of the company as a growth-oriented biotech. This reclassification could attract more growth-focused institutional investors and amplify the impact of future clinical and regulatory milestones for its drug PYRUKYND. Despite this shift, the core investment narrative still hinges on PYRUKYND's expansion into thalassemia and sickle cell disease, alongside managing losses and potential safety concerns, while the fair value is projected at $40.88 by 2029.
Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 A.m. ET
Agios Pharmaceuticals will host a conference call and webcast on July 30, 2026, at 8:00 A.M. ET to discuss its second-quarter 2026 financial results. The company invites investors and the public to participate in this event.
Agios Pharmaceuticals to announce Q2 2026 results on July 30
Agios Pharmaceuticals will announce its second quarter 2026 financial results and business highlights on July 30, 2026, at 8:00 a.m. ET, via a conference call and live webcast. The event will provide updates on the company's performance and strategic developments, with a replay available on their website. Agios Pharmaceuticals is a commercial-stage biopharmaceutical company focusing on innovative medicines for rare diseases.
Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) announced it will host a conference call and live webcast on Thursday, July 30, 2026, at 8:00 a.m. ET to report its second quarter 2026 financial results and business highlights. The event will be accessible via the Investors section of the company’s website, with a replay available afterward. Agios is a commercial-stage biopharmaceutical company focused on developing innovative medicines for patients with rare diseases.
Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at ...
Agios Pharmaceuticals, Inc. announced it will host a conference call and live webcast on Thursday, July 30, 2026, at 8:00 a.m. ET to report its second quarter 2026 financial results and business highlights. The event will be accessible via the Investors section of the company's website, with a replay available approximately two hours after the live webcast. Agios is a commercial-stage biopharmaceutical company focused on developing innovative medicines for rare diseases.
Agios Pharmaceuticals, Inc.(NasdaqGS: AGIO) added to Russell 2000 Growth Benchmark
Agios Pharmaceuticals, Inc. (NasdaqGS: AGIO) has been added to the Russell 2000 Growth Benchmark. The biopharmaceutical company focuses on developing therapies for rare diseases, with its lead product candidate, PYRUKYND (mitapivat), being a first-in-class pyruvate kinase activator for adults with PK deficiency. The company is actively engaged in developing several other product candidates and has recently presented positive Phase 3 results for mitapivat in sickle cell disease and entered a global licensing agreement for Cevidoplenib.
Agios Pharmaceuticals, Inc.(NasdaqGS: AGIO) added to Russell 3000E Growth Benchmark
Agios Pharmaceuticals, Inc. (AGIO) has been included in the Russell 3000E Growth Benchmark. This news highlights the company's growth trajectory and potentially broadens its appeal to institutional investors tracking Russell indices. The article also provides recent stock performance and an overview of Agios's biopharmaceutical focus on rare diseases, including its lead product candidate PYRUKYND.
Agios Pharmaceuticals Insider Lowered Holding By 91% During Last Year
This article analyzes the insider trading activity at Agios Pharmaceuticals (NASDAQ:AGIO) over the last year. It highlights that insiders, on average, sold 91% of their holdings, with Director Jeffrey David Karp being the largest individual seller by value. Despite insider selling, the stock has gained 6.1% over the past year.
Agios Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:AGIO)
This article provides an overview of Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) stock performance, financial estimates, and analyst forecasts. It covers key metrics such as current stock price, market capitalization, volatility, earnings, revenue, and EBITDA, along with historical highs and lows. The content emphasizes financial data and expert opinions to help investors make informed decisions.
Agios Pharmaceuticals, Inc. Actuals & Estimates (DUS:8AP)
This article provides an overview of Agios Pharmaceuticals, Inc. (DUS:8AP) stock, including its financial actuals, analyst estimates, and frequently asked questions. It covers earnings, revenue, net income, EBITDA, and historical price performance, along with information on when the next earnings report is due. The company does not currently pay dividends to shareholders.
AGIO Forecast — Price Target — Prediction for 2027
This article provides an in-depth forecast and analysis for Agios Pharmaceuticals, Inc. (AGIO) stock, including analyst price targets, historical performance, and key financial metrics. It highlights current stock prices, volatility, market capitalization, earnings reports, and revenue figures, alongside frequently asked questions about investing in AGIO.
Agios Pharmaceuticals (AGIO) Could Be 11% Undervalued Following Its Rare Disease Growth Narrative
Agios Pharmaceuticals (AGIO) has recently seen its stock price rise, suggesting a strengthening momentum. The company is considered 11.2% undervalued with an estimated fair value of $40.88, driven by expectations of FDA approval and commercial launch of PYRUKYND for thalassemia. However, potential safety questions for PYRUKYND and reliance on a concentrated rare disease portfolio present challenges.
A Quick Look at Today's Ratings for Agios Pharmaceuticals(AGIO.US), With a Forecast Between $36 to $54
This article provides a brief overview of recent analyst ratings for Agios Pharmaceuticals (AGIO.US), highlighting a forecasted price range of $36 to $54. It indicates that analysts generally maintain a favorable outlook for the company, as evidenced by the target price range. The content suggests that the pharmaceutical company's prospects are being viewed positively by market experts.
Precision Trading with Agios Pharmaceuticals Inc. (AGIO) Risk Zones
This article provides an AI-generated analysis of Agios Pharmaceuticals Inc. (AGIO), highlighting near and mid-term strong sentiment but a weak long-term outlook. It outlines three trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal analysis for support and resistance levels.
Agios Pharmaceuticals (AGIO) Is Up 10.3% After New Mitapivat Phase 3 Data and Share Filing – Has The Bull Case Changed?
Agios Pharmaceuticals recently presented new 52-week Phase 3 RISE UP data for mitapivat in sickle cell disease, showing clinically meaningful reductions in transfusion burden. This data strengthens the case for mitapivat's clinical relevance and supports the company's pursuit of
[Form 4] AGIOS PHARMACEUTICALS, INC. Insider Trading Activity
AGIOS PHARMACEUTICALS, INC.'s Chief Legal Officer, James William Burns, reported insider trading activity involving routine equity compensation changes. He received a grant of 3,000 restricted stock units and exercised 3,000 performance share units into common stock. The performance share units were granted on March 1, 2025, and their vesting is tied to specific clinical and research milestones, one of which was met as of June 18, 2026.
AGIOS (AGIO) director Maykin Ho exercises RSUs and receives new equity awards
AGIOS Pharmaceuticals director Maykin Ho reported compensation-related equity transactions, including exercising 2,816 restricted stock units (RSUs) into common stock, which increased her direct holdings to 19,848 shares. She also received new grants of 14,950 stock options and 2,927 restricted stock units, which will vest in future years. These transactions are part of her director compensation and indicate no open-market purchases or sales.
AGIOS (AGIO) director Scadden exercises RSUs and receives new stock option and RSU awards
AGIOS PHARMACEUTICALS, INC. director David Scadden increased his equity-based holdings through the exercise of restricted stock units (RSUs) and new equity awards. On June 18, 2026, he acquired 2,816 shares of common stock from RSU exercise, increasing his direct ownership to 20,419 shares. Scadden also received new grants of 14,950 stock options with a $34.16 exercise price and 2,927 restricted stock units, both vesting fully on June 18, 2027.
Agios Pharmaceuticals (AGIO) director reports new equity awards and RSU vesting
Agios Pharmaceuticals director Kaye I. Foster-Cheek reported routine equity compensation and an option-related share delivery. On June 18, 2026, she exercised restricted stock units for 2,816 shares, increasing her direct holdings to 10,284 shares, and also received 14,950 stock options and 2,927 restricted stock units. These transactions are compensation-related and not open-market purchases or sales, with indirect holdings also noted through a family trust.
[Form 4] AGIOS PHARMACEUTICALS, INC. Insider Trading Activity
AGIOS PHARMACEUTICALS, INC.'s Chief Commercial Officer, Tsveta Milanova, reported changes in her equity-based compensation as detailed in a Form 4 SEC filing. The filing indicates she received 3,000 restricted stock units and acquired 3,000 shares from exercised performance share units tied to specific clinical and research milestones. As a result, her direct holdings after these transactions include 9,000 performance share units and 3,000 restricted stock units.
Agios (NASDAQ: AGIO) CMO awarded RSUs, hits milestone for performance units
Agios Pharmaceuticals' Chief Medical Officer, Sarah Gheuens, received 3,000 restricted stock units and exercised 3,000 performance share units on June 18, 2026. This activity follows the achievement of a research milestone for performance units originally granted in March 2025, with related shares set to vest on December 31, 2027, subject to her continued service. Following these transactions, Gheuens now holds 3,000 restricted stock units and 9,000 performance share units, with no sales reported.
Agios (NASDAQ: AGIO) director exercises RSUs and gains new equity awards
Agios Pharmaceuticals director Rahul D. Ballal exercised 2,816 restricted stock units (RSUs) into common stock, increasing his direct holdings to 15,230 shares. Concurrently, he was granted 14,950 new stock options with an exercise price of $34.16 and 2,927 new restricted stock units. These new equity awards, granted on June 18, 2026, are scheduled to vest in full on June 18, 2027.
Agios (NASDAQ: AGIO) director receives new stock options and RSU awards
Agios Pharmaceuticals director Jeffrey D. Capello reported equity awards, including the conversion of 2,816 restricted stock units into common shares, increasing his direct holdings to 10,865 shares. He also received new grants of 14,950 stock options with an exercise price of $34.16 and 2,927 restricted stock units, both vesting on June 18, 2027. These transactions are compensation-related and do not involve open-market purchases or sales.
Agios Pharmaceuticals (AGIO) Is Up 10.3% After New Mitapivat Phase 3 Data and Share Filing – Has The Bull Case Changed?
Agios Pharmaceuticals (AGIO) saw a 10.3% increase following new Phase 3 data for mitapivat in sickle cell disease and a share filing. The new data shows mitapivat reduces transfusion burden and offers stronger outcomes for hemoglobin responders, strengthening its clinical relevance. However, the company still faces challenges with persistent operating losses and reliance on additional capital.
AGIO Stock Surges 35% in Six Months: What's Driving It?
Agios Pharmaceuticals (AGIO) shares have surged 35% over the past six months, fueled by investor confidence in its commercial products, especially mitapivat (Pyrukynd and Aqvesme), which has seen strong adoption and label expansion. Recent FDA approval for Aqvesme in thalassemia, global expansion efforts, and a strategic in-licensing agreement for cevidoplenib (for ITP) are key drivers,尽管该公司在LR-MDS研究中遇到了挫折. The company (AGIO) is currently a Zacks Rank #3 (Hold) stock.
Agios Pharmaceuticals (NASDAQ: AGIO) boosts 2023 stock plan by 2M shares
Agios Pharmaceuticals (NASDAQ: AGIO) stockholders approved an amendment to its 2023 Stock Incentive Plan, increasing the number of shares available for issuance by 2,000,000 and raising the limit for incentive stock options by the same amount. This decision, made at the 2026 annual meeting, also included the election of directors Rahul Ballal, Brian Goff, and Cynthia Smith. The amendment aims to enhance the company's ability to grant future equity awards and align employee incentives with company performance.
AGIO Stock Surges 35% in Six Months: What's Driving It?
Shares of Agios Pharmaceuticals (AGIO) have increased by 35% in the past six months due to growing investor confidence in its marketed products, mitapivat (Pyrukynd and Aqvesme), and positive regulatory developments. The FDA approval of Aqvesme in December 2025 for thalassemia was a significant catalyst, leading to strong early adoption and revenue growth for mitapivat. Agios is also expanding mitapivat's label for sickle cell disease and has in-licensed cevidoplenib for immune thrombocytopenia, despite a recent setback with tebapivat's failure in LR-MDS.
Agios Pharmaceuticals (AGIO) Stock Could Be 22% Undervalued After RISE UP Phase 3 Data
Agios Pharmaceuticals (AGIO) stock is gaining attention after releasing detailed 52-week data from its RISE UP Phase 3 trial for mitapivat in sickle cell disease, showing a recent share price increase. While short-term returns are positive, the 1-year total shareholder return is still down. The company's stock is considered 22.1% undervalued by a popular narrative, with a fair value of $40.88, driven by the anticipated FDA approval and commercial launch of PYRUKYND for thalassemia, though significant valuation risks remain due to a high P/S ratio compared to industry averages and potential setbacks.
Agios Pharmaceuticals Inc (AGIO) Earnings Forecast: Future EPS & Revenue Growth Estimates
Agios Pharmaceuticals Inc (AGIO) has an earnings forecast score of 8.00, ranking 163rd in its industry, with an average price target of $32.00. Based on 10 analyst ratings, the consensus is a "Buy" for AGIO stock. The company's expected revenue for the next quarter is $27.06 million, and EPS for the previous quarter was -$1.85, with an expectation of -$1.67 for the next quarter.
Agios Pharmaceuticals Inc (AGIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Agios Pharmaceuticals Inc (AGIO), detailing its business segments, regional revenue, and profit contribution. It notes that relevant data for recent fiscal years (FY2025, FY2025Q3, FY2025Q2, FY2025Q1) has not yet been disclosed by the company. However, it does provide historical regional revenue data, showing $54.03 million for the United States with a 0.00% proportion, indicating a placeholder or incomplete data.
Agios Pharmaceuticals (AGIO) Stock Could Be 22% Undervalued After RISE UP Phase 3 Data
Agios Pharmaceuticals (AGIO) is gaining attention after releasing detailed 52-week data from its RISE UP Phase 3 trial for mitapivat in sickle cell disease, with shares showing recent momentum. Despite short-term gains, the stock's one-year return is still down. A valuation narrative suggests the stock is 22.1% undervalued with a fair value of $40.88, driven by potential FDA approval and commercial launch of PYRUKYND for thalassemia, though significant risks remain regarding clinical outcomes and expenses.
AGIOS (AGIO) director Catherine Owen Adams converts 1,976 RSUs into common stock
AGIOS director Catherine Owen Adams converted 1,976 restricted stock units (RSUs) into common stock, resulting in her holding 8,049 shares directly. The RSUs were granted on June 13, 2023, and vest in three equal annual installments starting June 13, 2024. This transaction, categorized as neutral in impact and sentiment, involved no sales of shares.
Agios (NASDAQ: AGIO) director converts 1,976 RSUs, holds 8,049 shares
Agios (NASDAQ: AGIO) director Jeffrey D. Capello converted 1,976 restricted stock units (RSUs) into common shares on June 13, 2026. This transaction represents a compensation-related equity award, not an open-market purchase, and brings his direct holdings to 8,049 shares of Agios common stock. The RSUs were originally granted on June 13, 2023, with vesting scheduled in three equal annual installments beginning June 13, 2024.
Agios Pharmaceuticals (AGIO) Is Up 7.4% After Mitapivat RISE UP Data in Sickle Cell Disease - Has The Bull Case Changed?
Agios Pharmaceuticals' stock rose 7.4% after presenting positive 52-week Phase 3 RISE UP data for mitapivat in sickle cell disease, showing significant hemoglobin responses and reduced transfusion burden. While overall pain crises and fatigue endpoints were not statistically different, responders experienced improvements in these areas. The data strengthens the anti-hemolytic case for mitapivat and highlights the company's strategy to broaden its rare hematology pipeline with assets like cevidoplenib from Oscotec.
Agios Pharmaceuticals (AGIO) Is Up 7.4% After Mitapivat RISE UP Data in Sickle Cell Disease - Has The Bull Case Changed?
Agios Pharmaceuticals' stock rose 7.4% following the release of detailed 52-week Phase 3 RISE UP data for its drug mitapivat in sickle cell disease, which demonstrated significant hemoglobin responses and reduced transfusion burden. While overall pain crises and fatigue endpoints were not statistically different, hemoglobin responders showed notable improvements, strengthening the drug's anti-hemolytic profile. This data supports Agios's regulatory path and investment narrative, especially with the addition of a second late-stage rare hematology asset, cevidoplenib.
Agios Pharmaceuticals (AGIO) Is Up 7.4% After Mitapivat RISE UP Data in Sickle Cell Disease - Has The Bull Case Changed?
Agios Pharmaceuticals' stock saw a 7.4% climb after presenting positive 52-week Phase 3 RISE UP data for its drug mitapivat in sickle cell disease, showing significant hemoglobin responses and reduced transfusion burden. While overall pain crises and fatigue endpoints didn't reach statistical significance, patients who responded to mitapivat showed marked improvements. This data strengthens the investment narrative for Agios, especially as it seeks to expand beyond its single commercial product.
Agios Pharmaceuticals Touts Mitapivat Gains Despite Sickle Cell Pain Miss
Agios Pharmaceuticals highlighted new clinical data for its lead drug mitapivat in thalassemia and sickle cell disease, outlining a strategy to expand its rare disease pipeline. While mitapivat showed promising hemoglobin responses in both conditions, especially in sickle cell disease, it missed the pain reduction endpoint in the RISE UP trial for sickle cell patients. The company is advancing other programs and plans a confirmatory phase 3 trial for mitapivat in sickle cell disease, aiming for a broader label.
AGIO: Mitapivat shows durable efficacy in rare hematology, supporting growth and pipeline expansion
Agios Pharmaceuticals (AGIO) presented key data at EHA 2026, demonstrating the durable efficacy of mitapivat in treating thalassemia and sickle cell disease. The company is experiencing strong early commercial adoption and is focused on expanding its PK activation franchise and advancing late-stage pipeline assets to address multiple rare hematology indications.
Agios Pharmaceuticals Reports Positive Phase 3 Results for Mitapivat in Sickle Cell Disease, Highlighting Hemoglobin Response and Reduced Transfusion Burden
Agios Pharmaceuticals announced positive Phase 3 results from its RISE UP trial for mitapivat in sickle cell disease, showing statistically significant improvements in hemoglobin response and a meaningful reduction in transfusion burden. While the primary endpoint for reducing pain crises was not met, responsive patients experienced improvements in pain, fatigue, and quality of life. The drug was well-tolerated, and Agios plans to discuss these findings further with investors.
Agios presents detailed mitapivat trial results for sickle cell
Agios Pharmaceuticals, Inc. presented detailed 52-week results from its RISE UP Phase 3 trial of mitapivat for sickle cell disease. The trial showed 40.6% of patients in the mitapivat arm achieved hemoglobin response, a significant improvement over placebo, and a reduction in blood transfusions and pain crises for responders. Despite not meeting the primary endpoint for pain crises reduction across the entire mitapivat arm, the drug was well-tolerated, and Agios has submitted a supplemental New Drug Application for accelerated approval.
Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong ...
Agios Pharmaceuticals presented detailed results from its RISE UP Phase 3 trial of mitapivat for sickle cell disease at EHA 2026. The drug demonstrated statistically significant improvement in hemoglobin response, reduced transfusion burden, and improved patient-reported outcomes for pain and fatigue. Mitapivat was also well-tolerated, with a safety profile consistent with previous trials.
